Lianne G. Singer

Lianne G. Singer

Auto-generated profile, based on publicly available information

Lianne G. Singer

Division of Respirology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
DWDavid Weill
David Weill
CBChristian Benden
Christian Benden
PCPaul A. Corris
Paul A. Corris
JDJohn H. Dark
John H. Dark
RDR. Duane Davis
R. Duane Davis
AGAllan R. Glanville
Allan R. Glanville

14 April 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MCMarcelo Cypel
Marcelo Cypel
JYJonathan C. Yeung
Jonathan C. Yeung
MLMingyao Liu
Mingyao Liu
MAMasaki Anraku
Masaki Anraku
FCFengshi Chen
Fengshi Chen
SKShaf Keshavjee
Shaf Keshavjee
More than 80% of donor lungs are potentially injured and therefore not considered suitable for transplantation. With the use of normothermic ex vivo lung perfusion (EVLP), the retrieved donor lung can be perfused in an ex vivo circuit, providing an opportunity to reassess its function before transplantation. In this study, we examined the feasibility of transplanting high-risk donor lungs that have undergone EVLP. In this prospective, nonrandomized clinical trial, we subjected lungs considered to be high risk for transplantation to 4 hours of EVLP. High-risk donor lungs were defined by specific criteria, including pulmonary edema and a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PO2:FIO2) less than 300 mm Hg. Lungs with acceptable function were subsequently transplanted. Lungs that were transplanted without EVLP during the same period were used as controls. The primary end point was primary graft dysfunction 72 hours after transplantation. Secondary end points were 30-day mortality, bronchial complications, duration of mechanical ventilation, and length of stay in the intensive care unit and hospital. During the study period, 136 lungs were transplanted. Lungs from 23 donors met the inclusion criteria for EVLP; in 20 of these lungs, physiological function remained stable during EVLP and the median PO2:FIO2 ratio increased from 335 mm Hg in the donor lung to 414 and 443 mm Hg at 1 hour and 4 hours of perfusion, respectively (P<0.001). These 20 lungs were transplanted; the other 116 lungs constituted the control group. The incidence of primary graft dysfunction 72 hours after transplantation was 15% in the EVLP group and 30% in the control group (P=0.11). No significant differences were observed for any secondary end points, and no severe adverse events were directly attributable to EVLP. Transplantation of high-risk donor lungs that were physiologically stable during 4 hours of ex vivo perfusion led to results similar to those obtained with conventionally selected lungs. (Funded by Vitrolife; ClinicalTrials.gov number, NCT01190059.)

28 April 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
FMFrancis X. McCormack
Francis X. McCormack
YIYoshikazu Inoue
Yoshikazu Inoue
JMJoel Moss
Joel Moss
LSLianne G. Singer
Lianne G. Singer
HWHongjun Wang
Hongjun Wang
BTBruce C. Trapnell
Bruce C. Trapnell
Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1–2 trials involving patients with LAM. We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment — a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV1). During the treatment period, the FEV1 slope was −12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV1 during the treatment period was 153 ml, or approximately 11% of the mean FEV1 at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups. In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648.)

1 July 2006 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JOJonathan B. Orens
Jonathan B. Orens
MEMarc Estenne
Marc Estenne
SASelim Arcasoy
Selim Arcasoy
JCJohn V. Conte
John V. Conte
PCPaul Corris
Paul Corris
AGAllan R. Glanville
Allan R. Glanville

1 July 2011 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MSMasaaki Sato
Masaaki Sato
TWThomas K. Waddell
Thomas K. Waddell
UWUte Wagnetz
Ute Wagnetz
HRHeidi C. Roberts
Heidi C. Roberts
DHDavid M. Hwang
David M. Hwang
SKShaf Keshavjee
Shaf Keshavjee

12 May 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JCJill I. Cameron
Jill I. Cameron
LCLeslie M. Chu
Leslie M. Chu
AMAndrea Matte
Andrea Matte
GTGeorge A. Tomlinson
George A. Tomlinson
LCLinda Chan
Linda Chan
MHMargaret S. Herridge
Margaret S. Herridge
Few resources are available to support caregivers of patients who have survived critical illness; consequently, the caregivers’ own health may suffer. We studied caregiver and patient characteristics to determine which characteristics were associated with caregivers’ health outcomes during the first year after patient discharge from an intensive care unit (ICU). We prospectively enrolled 280 caregivers of patients who had received 7 or more days of mechanical ventilation in an ICU. Using hospital data and self-administered questionnaires, we collected information on caregiver and patient characteristics, including caregiver depressive symptoms, psychological well-being, health-related quality of life, sense of control over life, and effect of providing care on other activities. Assessments occurred 7 days and 3, 6, and 12 months after ICU discharge. The caregivers’ mean age was 53 years, 70% were women, and 61% were caring for a spouse. A large percentage of caregivers (67% initially and 43% at 1 year) reported high levels of depressive symptoms. Depressive symptoms decreased at least partially with time in 84% of the caregivers but did not in 16%. Variables that were significantly associated with worse mental health outcomes in caregivers were younger age, greater effect of patient care on other activities, less social support, less sense of control over life, and less personal growth. No patient variables were consistently associated with caregiver outcomes over time. In this study, most caregivers of critically ill patients reported high levels of depressive symptoms, which commonly persisted up to 1 year and did not decrease in some caregivers. (Funded by the Canadian Institutes of Health Research and others; ClinicalTrials.gov number, NCT00896220.)